Close Menu

NEW YORK (GenomeWeb) – Investment bank Piper Jaffray has upgraded its rating on Genomic Health's stock to overweight, maintaining a price target for shares of $72, based on an assessment of the current pace of the company's business ahead of a German reimbursement decision that is expected to finalize today.

In a note to investors, analyst William Quirk said that the company's stock has been off significantly since it announced its Q1 earnings, necessitating the rating upgrade to maintain the existing price target.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A federal judge has ruled that drug companies, device manufacturers, and universities need to provide missing clinical data from hundreds of trials to a federal website, ScienceInsider reports.

A genetic analysis suggests red pandas might actually belong to two different species, New Scientist reports.

NPR reports that the US Centers for Disease Control and Prevention has fixed the problem with some of its SARS-CoV-2 testing kits.

In Nature this week: epigenetic factors that prevent healthy aging and more.